Covered recipient · General Payments record
JULIO CESAR ALVARENGA THIEBAUD
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
General Payments · PY2018–2024
$9,532.69
- Reported across 26 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $6,900.00 | 2 |
| Travel and Lodging | $875.01 | 2 |
| Food and Beverage | $647.02 | 10 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Incyte Corporation | $5,966.29 | 7 |
| Gamida Cell Inc. | $2,093.43 | 2 |
| Stemline Therapeutics Inc. | $109.33 | 1 |
| Kite Pharma, Inc. | $100.05 | 1 |
| Tempus AI, Inc | $95.74 | 1 |
| ABBVIE INC. | $39.43 | 1 |
| GlaxoSmithKline, LLC. | $17.76 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (14)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $39.43 | 04/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103214693 | CMS |
| Gamida Cell Inc. | $143.43 | 08/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144440996 | CMS |
| Gamida Cell Inc. | $1,950.00 | 09/19/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1144440998 | CMS |
| GlaxoSmithKline, LLC. | $17.76 | 10/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115937975 | CMS |
| Incyte Corporation | $11.28 | 02/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141299395 | CMS |
| Incyte Corporation | $613.95 | 11/08/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1141222918 | CMS |
| Incyte Corporation | $50.00 | 11/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141170431 | CMS |
| Incyte Corporation | $50.00 | 11/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141170559 | CMS |
| Incyte Corporation | $30.00 | 11/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141184396 | CMS |
| Incyte Corporation | $261.06 | 11/09/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1141318051 | CMS |
| Incyte Corporation | $4,950.00 | 11/14/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141222220 | CMS |
| Kite Pharma, Inc. | $100.05 | 10/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1128614223 | CMS |
| Stemline Therapeutics Inc. | $109.33 | 07/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142961093 | CMS |
| Tempus AI, Inc | $95.74 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150160222 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2021, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.